364042-47-7

Basic information

• Product Name: A 419259 trihydrochloride
• Synonyms: A 419259 trihydrochloride;A 419259;A419259;A-419259;RK 20449;RK20449;RK-20449;7-[Trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trihydrochloride
• CAS NO: 364042-47-7
• Molecular Formula: C29H37Cl3N6O
• Molecular Weight: 592.00268
• Mol File: 364042-47-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 686.4±55.0 °C(Predicted)
• Appearance: white to beige/
• Density: 1.29±0.1 g/cm3(Predicted)
• Storage Temp.: room temp
• Solubility: H2O: soluble10mg/mL (clear solution)
• PKA: 8.20±0.42(Predicted)
• CAS DataBase Reference: A 419259 trihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: A 419259 trihydrochloride(364042-47-7)
• EPA Substance Registry System: A 419259 trihydrochloride(364042-47-7)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 364042-47-7(Hazardous Substances Data)

Usage

Description

A-419259 is an inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, <3, <3, and 11.26 nM, respectively)., It is selective for these kinases over c-Abl (IC50 = 3,000 nM) and PKC (IC50 = >33 μM). A-419259 inhibits growth of Philadelphia chromosome-positive (Ph+) K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 μM, respectively), but not Ph- TF-1 and HEL cells. It induces apoptosis in K-562 cells in a concentration-dependent manner. A-419259 (300 nM) inhibits differentiation of murine embryonic stem cells while maintaining pluripotency. It reduces the total number of acute myeloid leukemia (AML) cells, as well as AML stem cells, in the bone marrow and spleen in mouse patient-derived xenograft (PDX) models of AML when administered at a dose of 30 mg/kg twice daily.

Uses

A 419259 Trihydrochloride is the hydrochloride form of A 419259 which is a Src kinase inhibitor and can be used in treatment of chronic myelogenous leukemia, lymphangioleiomyomatosis and tuberous sclerosis.

Upstream product

• 22428-87-1 4,4-ethylenedioxycyclohexan-1-ol 
• 123148-78-7 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine 
• 262441-40-7 5-(4-phenoxyphenyl)-7-(1,4-dioxaspiro[4,5]decan-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 490030-16-5 4-chloro-5-(4-phenoxyphenyl)-7-(1,4-dioxaspiro[4.5]decan-8-yl)-7H-pyrrolo[2,3-d]pyrimidine 
• 262444-48-4 4-chloro-7-(1,4-dioxaspiro[4.5]decan-8-yl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidine 
• 109-01-3 1-methyl-piperazine 
• 262433-52-3 4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-one 

Relevant articles and documents

COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA

Provided herein are compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells.

Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck.

A series of pyrrolo[2,3-d]pyrimidines was synthesized and evaluated as inhibitors of Lck. Lck accommodates a diverse set of substituents at N-7. Altering the substituent at N-7 provided compound 13, an orally available lck inhibitor which inhibited TCR me